FABP4 and hepatocellular carcinoma: Taken together, these results indicate that FABP4 low‐expression plays a critical role in the proliferation and metastasis of HCC cells, and maybe a biomarker for HCC diagnosis and prognosis, and may provide an emerging therapeutic target for HCC in future.